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Fibre-optic bronchoscopy was performed in local anaesthesia using lignocaine. Serum concentrations of lignocaine 
and its active metabolite monoethylglycinexylidide (MEGX) were measured in 16 patients at regular intervals up to 
120 min after administration. Lignocaine was administered as an aerosol in the upper respiratory tract and as a 
solution in the bronchial tree. The total dose of lignocaine ranged from 243 to 608 mg (2.4-8.0 mg kg- ’ body 
weight). The dose of lignocaine given as an aerosol ranged from 163 to 508 mg (1.6-6.6 mg kg- ‘) and the dose given 
as a solution ranged from 60 to 180 mg (0.8-2.5 mg kg ~ ‘). The highest median serum lignocaine concentration, 
10.5,~mol 1~ ‘, was measured 20 min after administration. None of the patients had toxic serum lignocaine levels 
(>26 pmol 1~ ‘) or adverse effects. The highest median serum MEGX concentration, 1.7 pmol 1 - I, was measured 
120 min after administration. The dose of lignocaine, expressed in mg per kg body weight correlated with serum 
lignocaine and serum MEGX (r,=O.47 and r,=O.39, respectively). Lignocaine is a clinically safe, local anaesthetic 
agent provided the total dose does not exceed 6-7 mg kg - ’ body weight. 
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Introduction 
The fibre-optic bronchoscope became commercially avail- 
able in 1967, and is at present the most important invasive 
diagnostic instrument in the evaluation of pulmonary dis- 
eases (1). Worldwide, the number of fibre-optic broncho- 
scopies (FOB) per year are steadily increasing. Fibre-optic 
bronchoscopies can be performed in local anaesthesia, a 
procedure which has gained widespread acceptance due to 
excellent patient tolerability, low costs, convenience for 
examination on an outpatient basis and low incidence of 
complications (1,2). In large series, at least 95% of the 
diagnostic bronchoscopies can be done in local anaesthesia 
(2). 
The purpose of the present study was to measure serum 
lignocaine concentrations during FOB to ensure that 
present guidelines for local anaesthesia did not carry an 
unnecessary risk for lignocaine toxicity. 
Materials and Methods 
As part of the diagnostic evaluation of a pulmonary lesion, 
16 patients (five men) with a median age of 63 years (range 
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46-80 years) had a FOB performed in local anaesthesia. 
The FOB were performed by five different operators. All 
subjects had normal renal function, normal electrocardio- 
gram and no clinical evidence of cardiac disease. Fourteen 
subjects had normal biochemical liver tests (serum 
bilirubin, serum aminotransferase, serum alkaline phos- 
phatase, plasma prothrombin time), and two subjects had 
slightly elevated serum alkaline phosphatase. The patients’ 
body surface was calculated according to Du Bois’ formula 
(surface = weight0.425 x height0’725 x 0.007184). 
Premeditation consisted of peroral diazepam 10 mg and 
intramuscular atropine 0.5 mg prior to FOB. If necessary, 
additional sedation, intravenous midazolam 1.25-2.50 mg, 
was given during the procedure through an indwelling 
venous catheter. 
In cavum nasi, rhinopharynx, oropharynx, larynx and 
rima glottidis, local anaesthesia was obtained with a pres- 
surized lignocaine aerosol (Leostesin Spraya, Lsvens 
Kemiske Fabrik DK-2750 Ballerup) containing 41 mg 
lignocaine per gram of aerosol. This procedure lasted 
approximately 3 min. The administered dose of lignocaine 
was calculated by weighing the canister before and after 
spraying. 
Following transnasal introduction of the fibre-optic 
bronchoscope (Olympus lT20D), a solution of cocaine, 
40 mg 1~ ’ (5 ml), was applicated to the vocal cords, rima 
glottidis and trachea. After 2-3 min, the bronchoscope was 
introduced through the rima glottidis into the trachea. As a 
standard procedure, a solution of lignocaine 10 mg ml - ’ 
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FIG. 1. Serum lignocaine concentrations (medians and 
S-95% confidence limits) in 16 subjects during fibre-optic 
bronchoscopy in local anaesthesia. 
was applicated in the trachea (2 ml), in the right (2 ml) and 
the left (2 ml) main bronchus. Additional lignocaine sol- 
ution was administered according to the intensity of the 
patient’s cough. 
Blood samples were taken through the venous catheter at 
the following times: 0 (immediately before) 5, 10, 20, 30, 60 
and 120 min after the administration of lignocaine spray. 
Serum was separated within 45 min after blood sampling, 
frozen at - 20°C and analysed in the same series. Serum 
lignocaine and serum MEGX were measured by high- 
pressure liquid chromatography (3). 
In the pharmacokinetic analysis, the area under the curve 
(AUC) was calculated using the linear trapezoidal rule. 
Non-parametric statistics were employed in the analysis of 
the data. Correlations were assessed by Spearman’s rank 
correlation coefficient (7,). 
Results 
There were no complications at the bronchoscopies. The 
dose of lignocaine given by spray ranged from 163 to 
508 mg (1.6-6.6 mg kg ~ ’ body weight; 79.8-291.2 mg m-’ 
body surface), and the dose given as solution ranged from 
60 to 180 mg (0.8-2.5 mg kg- ‘; 35.5-100.0 mg m-‘). The 
total dose (spray+ solution) of lignocaine ranged from 243 
to 608 mg (2.4-8.0 mg kg - ‘; 119.0-348.5 mg m - 2). 
Figure 1 shows the longitudinal variation in the median 
serum lignocaine concentrations. The maximum median 
serum lignocaine concentration, 10.5pmol l-l, was 
measured 20 min after administration of lignocaine. Two 
patients, both women, demonstrated serum lignocaine con- 
centrations above 20 hmol l- I. One, having an elevated 
serum alkaline phosphatase, received a total of 347 mg 
lignocaine (6.2 mg kg- ‘) yielding a maximum serum 
concentration of 21.6pmol 1 - ‘. The other, having normal 
liver function, received a total of 344 mg lignocaine (4.8 mg 
kg- ‘) yielding a maximum serum concentration of 
22.5 pmol l- ‘. Their serum lignocaine elimination curves 
did not differ from those of the other patients. None 
of the 16 participants had any symptoms of lignocaine 
intoxication. 
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FIG. 2. Serum monoethylglycinexylidide (MEGX) concen- 
trations (medians and 5-95% confidence limits) in 16 sub- 
jects during fibre-optic bronchoscopy in local anaesthesia. 
Correlation coefficients were calculated between the total 
doses of lignocaine expressed in mg, in mg mp7 body 
surface as well as in mg kg - ’ body weight, and serum 
lignocaine concentrations at the different points of sam- 
pling 5-120 min after administration. There were no corre- 
lations (Ye ranging from 0.03 to 0.10) between the lignocaine 
doses in mg and serum lignocaine concentrations. Low 
correlation coefficients (v, ranging from 0.11 to 0.16) were 
found between the lignocaine doses in mg m ~ ’ and serum 
lignocaine. The highest correlation coefficients were 
observed between the lignocaine doses in mg kg - ’ and 
serum lignocaine at 30 min (v,=O.43, P=O.O9), at 60 min 
(v,=O.47, P=O.O7) and at 120 min (r,=0.41, P=O.ll). 
There were no correlations between AUC values for 
serum lignocaine and the doses of lignocaine (spray, sol- 
ution, spray+ solution), body surface area or biochemical 
liver function tests. 
Figure 2 shows the time-related variations in the median 
serum MEGX concentrations. Detectable concentrations 
were present 10 min after administration of lignocaine, and 
concentrations continued to rise during the observation 
period, although the increase diminished between 60 
and 120 min after administration. The maximum median 
serum MEGX concentration, 1.7 pmol 1~ ‘, was measured 
120 min after administration. The single individual 
maximum concentration was 3.5 pm01 1 - ‘, 
The combined median serum lignocaine and serum 
MEGX concentrations are shown in Fig. 3. Although two 
patients displayed combined serum concentrations above 
20 pmol l- I, none had concentrations above 26 pmol 1~ ‘. 
There were no correlations (I’, ranging from 0.02 to 0.07) 
between the total doses of lignocaine in mg and serum 
MEGX or serum MEGX+serum lignocaine concen- 
trations. Low correlation coefficients (I;. ranging from 0.08 
to 0.14) were found between the lignocaine doses in mg 
m ~’ and serum MEGX or serum MEGX+serum 
lignocaine. The highest correlation coefficients were 
observed between the lignocaine doses in mg kg ~ ’ and 
serum MEGX (at 120 min: r,=@39; P=O.14) and 
serum MEGX+serum lignocaine (at 30 min: 1;=0.36, 
P=O.17). 
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FIG. 3. Combined serum lignocaine+ serum monoethyl- 
glycinexylidide (MEGX) concentrations (medians) in 16 
subjects during fibre-optic bronchoscopy in local anaes- 
thesia. 
Discussion 
In the 194Os, bronchoscopy with the rigid bronchoscope 
was performed in local anaesthesia using cocaine and 
tetracaine (4). Lignocaine, which was introduced as a local 
anaesthetic agent around 1950, is now the most widely used 
agent at FOB. A survey of bronchoscopic practice among 
physicians in the United Kingdom in 1986 disclosed 
that 92% used lignocaine and 1% used cocaine for local 
anaesthesia (5). 
Local anaesthesia with lignocaine at FOB can be 
obtained in different ways of application. Some centres use 
a lignocaine spray in the cavum nasi, pharynx and larynx 
combined with inhalation of a lignocaine aerosol from a 
nebulizer (6,7). Additional lignocaine as a solution may be 
applied to the bronchial tree after the introduction of the 
bronchoscope (89). Many centres advocate the ‘spray as 
you go’ technique in which the airways are successively 
anaesthetized with lignocaine spray or solution as the 
bronchoscope is advanced into the bronchial tree (1,2). 
Other studies, using a combination of lignocaine spray in 
the upper airways and lignocaine solution introduced 
through the bronchoscope, have demonstrated that serum 
lignocaine peak concentrations are reached 20-40 min after 
administration (89) which is in accordance with the results 
of the present investigation. Following the inhalation of 
lignocaine aerosol, peak serum lignocaine concentrations 
are recorded at 20-30 min (6). 
The AUC value for serum lignocaine is determined by the 
absorbed fraction of the administered lignocaine dose in 
the relation to the elimination (clearance) of the drug. The 
great interindividual differences in both the absorbed frac- 
tion as well as the clearance explain the lack of a relation 
between the dose of lignocaine and AUC. 
Likewise, there was no correlation between the dose of 
lignocaine and the serum concentration. A similar obser- 
vation was reported in a study comprising 109 patients 
receiving an average of 587 mg lignocaine endobronchially 
during FOB (1 I). However, in the present series, a clinically 
relevant correlation was demonstrated between the dose of 
lignocaine in mg kg- ’ body weight and serum lignocaine. 
This means that body weight can be used for the adjustment 
of the lignocaine dose. 
The two methods of lignocaine applications, spray in the 
upper airways and solution in the lower airways, have 
different absorption profiles. Application of lignocaine on 
the mucous membranes in the upper airways yields peak 
serum lignocaine concentrations after 30-50 min, which are 
25-50% lower than if the same dose had been given 
intravenously (9). Instillation of lignocaine in the bronchial 
tree and alveoli yields a much faster absorption, which is 
almost comparable to intravenous administration (10). 
Cocaine may delay the absorption of lignocaine from the 
mucous membranes in the upper airways due to its vaso- 
constrictive effect. Furthermore, an unknown, variable 
fraction of the lignocaine instilled in the bronchial tree is 
removed by suction through the bronchoscope, and conse- 
quently is not available for absorption. The individual 
differences in the absorbed fraction of lignocaine and in the 
rate of hepatic metabolism contribute to reduce the corre- 
lations between the dose of lignocaine in mg kg - ’ and 
serum lignocaine concentrations. 
The half-life of lignocaine is 90-100 min (12). Lignocaine 
is metabolized in the liver by N-de-ethylation (12). The 
principal metabolite is MEGX, which has a half-life of 
70-100 min, i.e. similar to lignocaine (10,13). On a molar to 
molar relationship, MEGX has a local anaesthetic effect 
and a side-effect profile similar to lignocaine (12,13). 
All local anaesthetic agents are toxic in high doses (14). 
The experience concerning lignocaine toxicity is mainly 
derived from intravenous administration in the treatment of 
cardiac arrhythmias (12-l 5). The toxicity of lignocaine and 
MEGX affects the central nervous system (CNS) and the 
heart (14). The CNS intoxication symptoms, consisting of 
hyperexitation which may progress to convulsions (14), 
begin to appear at serum lignocaine concentrations of 
22-26 pmol 1 - ‘, occur occasionally in the range 
2643 umol 1~ ‘, and occur often at concentrations above 
43 pmol 1 - ’ (13-15). The cardiac intoxication symptoms 
consist of inhibition of the pacemaker activity and 
decreased contractility of the myocardium, leading to a 
falling cardiac output and hypotension (14). According to 
Harrison et al. (15), the therapeutic serum lignocaine range 
in cardiac arrhythmias is 6.4-26 pmol 1~ i. Cardiovascular 
collapse occurs at serum lignocaine concentrations exceed- 
ing 60-80pmol 1~ ’ (14). 
The CNS intoxication symptoms are readily recognized 
by clinical examination and can be treated with anticonvul- 
sive drugs such as benzodiazepines. In contrast, the cardio- 
vascular side-effects are serious and often do not respond to 
treatment (14). As the CNS symptoms occur at a serum 
lignocaine concentration which is approximately one-third 
of the concentration causing cardiovascular collapse, 
lignocaine has a broad therapeutic index, and is 
therefore considered to be a safe local anaesthetic agent at 
FOB. 
In previous studies of FOB in local anaesthesia, the total 
doses of lignocaine were in the range 200-600 mg (6,8-l 1). 
Even following lignocaine doses above 8 mg kg- ’ body 
weight, toxic serum concentrations were seldom observed 
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(6,8-l 1). However, serum MEGX was not analysed in these 
studies (6,8-l 1). The total dose of lignocaine in the present 
series was 1600 mg, corresponding to <8 mg kg- ’ body 
weight, and none of the patients had combined 
serum lignocaine+ serum MEGX concentrations above 
26pmolll’. 
We conclude that, at FOB, the risk of adverse effects 
attributed to local anaesthesia is negligible provided the 
dose of lignocaine does not exceed 6-7 mg kg - ’ body 
weight corresponding to 400-500 mg in a 70 kg man. 
Patients with cardiac and hepatic insufficiency have a lower 
clearance of lignocaine (10,12). In such patients, the dose of 
lignocaine should be reduced, and should not exceed 
445 mg kg - i body weight. 
According to the results of this study, we changed our 
guidelines for local anaesthesia at FOB, and replaced 
cocaine by lignocaine solution. More than 6000 FOB 
procedures have been performed in our centre without any 
toxic effects caused by lignocaine. 
Local anaesthesia at FOB can be achieved with a number 
of different agents and with a variety of techniques (10). It 
is important that the operator becomes familiar with one 
local anaesthetic agent and learns to manage one single 
technique. The induction of local anaesthesia should be 
simple, and should carry a minimum of risk and discomfort 
to the patient. Lignocaine, which is the most thoroughly 
investigated and best-described local anaesthetic agent, 
offers the widest margin of safety, and is advocated as 
the drug of choice for local anaesthesia at fibre-optic 
bronchoscopy. 
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